绝经后晚期乳腺癌新辅助内分泌治疗的疗效观察  

Efficacy of Neoadjuvant Endocrinotherapy for Postmenopausal Patients with Advanced Breast Cancer

作　　者：陆江[1] 李靖若[1] 张临风[1] 王燕[1] 张莹莹[1] 

机构地区：[1]郑州大学第一附属医院乳腺外二科,河南郑州450052

出　　处：《肿瘤基础与临床》2014年第3期234-236,共3页journal of basic and clinical oncology

摘　　要：目的探讨新辅助内分泌治疗对于绝经后晚期乳腺癌治疗的可行性,比较三苯氧胺与来曲唑的疗效。方法 51例绝经后乳腺癌晚期患者随机分为2组,三苯氧胺组26例采用三苯氧胺治疗,来曲唑组25例采用来曲唑治疗,比较并且分析2组的临床效果和毒副反应。结果来曲唑组的总有效率为68.0%,明显高于三苯氧胺组的30.7%,差异有统计学意义(P<0.05)。2组毒副反应均较轻。结论新辅助内分泌治疗对于绝经后晚期乳腺癌治疗安全有效,而且来曲唑治疗效果优于三苯氧胺。Objective To evaluate the feasibility of neoadjuvant endocrinotherapy for postmenopausal patients with advanced breast cancer, and compare the efficacy of tamoxifen and letrozole. Methods Fifty postmenopausal patients with advanced breast cancer were randomly divided into two groups, 26 patients of the tamoxifen group re- ceived tamoxifen treatment, and 25 patients of the letrozole group received letrozole treatment, the efficacy and toxici-ties of tamoxifen and letrozole were compared. Results The total effective rate of the letrozole group （68.0%） was obviously higher than that of the tamoxifen group （ 30.7 % ） （ P 〈 0.05 ）. The toxicities of the two groups were mild. Conclusion Neoadjuvant endocrino- therapy is effective snd safe for postmenopansal patients with advanced breast cancer, and letrozole has an advantage over tamoxifen.

关 键 词：乳腺癌 新辅助内分泌治疗 三苯氧胺 来曲唑 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]